Citrate Anticoagulation in Continuous Renal Replacement Therapy: Multicenter PICU Study of Filter-Related Outcomes

dc.contributor.authorKihtir, Hasan S.
dc.contributor.authorDuyu, Muhterem
dc.contributor.authorMementoglu, Mehmet E.
dc.contributor.authorTolunay, Ilknur
dc.contributor.authorKendirli, Tanil
dc.contributor.authorEkinci, Faruk
dc.contributor.authorBotan, Edin
dc.date.accessioned2025-05-10T15:24:05Z
dc.date.issued2024
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractObjectives: To examine citrate anticoagulation in continuous renal replacement therapy (CRRT) in the PICU. Design: Post hoc analysis of a curated, multicenter dataset collected from January 1, 2022, to June 1, 2023. Setting: Seven PICUs in Turkey. Patients: PICU admissions in need of CRRT, 28 days to 18 years old. Interventions: None. Measurements and Main Results: In 128 filters used in 73 patients, the effective filter life (EFL) restricted to 72 hours was a median (interquartile range [IQR]) of 40.5 hours (IQR, 21-58 hr); total EFL was a median of 59 hours (IQR, 28-89 hr). Analysis of the receiver operating characteristic curve for initial citrate infusion dose (CID) and whether EFL reached 72 hours identified a cutoff level for initial CID of greater than 2.64 mmol citrate per liter of patient blood flow (mmol/L-bf). As expected, the two filter groups categorized by initial CID (? 2.7 vs. < 2.7 mmol/L-bf) showed filters in children receiving higher initial dosing had longer total EFL (72 hr [IQR, 48-104 hr] vs. 38.5 hr [IQR, 18-84 hr]; p = 0.03). We failed to identify an association between CRRT for over 24 or 48 hours and greater odds (odds ratio [OR], 95% CI) of citrate accumulation (OR, 2.23; 95% CI, 0.82-6.13; p = 0.118 or OR, 1.78; 95% CI, 0.84-3.8; p = 0.134, respectively). However, we cannot exclude up to 6.1- or 3.8-fold odds of citrate accumulation; of note, CRRT over 72 hours was associated with greater odds of citrate accumulation (OR, 2.17; 95% CI, 1.01-4.68; p = 0.04). Citrate lock syndrome occurred in eight of 128 (6.3%; 95% CI, 3-11.4%) filters, and resolved without termination of CRRT. On multivariable analysis, a higher patient initial lactate concentration was associated with an 18% (95% CI, 7-30%) greater hazard of developing citrate accumulation. Conclusions: Citrate anticoagulation for CRRT is an option for children. Choosing an initial CID greater than or equal to 2.7 mmol/L-bf provides longer EFL but with the associated potential of citrate accumulation. Further studies are needed on initial CID and duration of EFL. © 2024 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
dc.identifier.doi10.1097/PCC.0000000000003661
dc.identifier.issn1529-7535
dc.identifier.pmid39699267
dc.identifier.scopus2-s2.0-85213686123
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1097/PCC.0000000000003661
dc.identifier.urihttps://hdl.handle.net/20.500.14730/6627
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofPediatric Critical Care Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250302
dc.subjectanticoagulation; citrate; citrate-related complications; continuous renal replacement therapy; effective filter life
dc.titleCitrate Anticoagulation in Continuous Renal Replacement Therapy: Multicenter PICU Study of Filter-Related Outcomes
dc.typeArticle

Dosyalar